SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

Anticipation of BlackBerrys upcoming Q2 earnings report is driving attention, with traders positioning for stronger guidance, QNX growth, and a potential pre-earnings move. Bulls are also highlighting QNXs physical-AI and robotics partnerships, while bears remain skeptical of revenue growth, management execution, and the likelihood of another post-earnings pullback.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Reported progress on the U.S. CLARITY Act and Ondo Finances DTCC Fund/SERV integration are driving attention around ONDO as a leading real-world-asset tokenization play. Traders remain divided over whether the tokens growth will translate into holder value, with the potential fee switch, dilution, and broader crypto-market direction central to the debate.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Merck and Modernas positive Phase 3 personalized cancer-vaccine results are driving attention, as traders view Personalis genomic technologyand Tempuss planned acquisition of Personalisas strategically validated. Bulls are also citing heavy short interest and call activity as potential squeeze fuel, while skeptics warn the move may be overextended and valuation remains demanding.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat is drawing attention after its Teal/FANG offerings reportedly failed to rank among the leading entries in the Drone Dominance Gauntlet II, raising concerns about future defense contracts and pressuring sentiment. Traders are split between those viewing the result and insider selling, dilution, and limited contract wins as evidence of management and execution problems, and bulls who argue the company remains positioned for Black Widow, Blue Ops, and later procurement opportunities.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Reported Robinhood integration and Uniswaps role as a liquidity venue for crypto and tokenized assets are driving attention, alongside discussion of fee-driven UNI buybacks and burns. Traders are broadly bullish on the potential for higher volume and deflationary supply, though some argue the developments are already priced in and point to overbought conditions or a possible pullback.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is drawing attention after CEO Dara Khosrowshahi disclosed a sizable open-market share purchase, following a separate purchase by COO Andrew Macdonald. Traders view the insider buying as a confidence signal and potential support for the stock, while others remain concerned about persistent weakness and competition from autonomous-vehicle platforms.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDAs full approval of Fayuvi, the first treatment for Sanfilippo syndrome type A, is driving attention to RARE, with traders highlighting a new commercial product and Priority Review Voucher. The community is broadly bullish but debates whether the muted share-price reaction reflects the therapys limited patient population, commercialization risks, and Ultragenyxs cash burn.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves convertible-debt financing and planned at-the-market share sales are driving attention, with traders focused on leverage, dilution, and the timing of the capital raise. Bears see continued financing pressure and weak shareholder economics, while bulls argue the funding supports expansion amid higher-priced compute contracts and strong customer demand.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Veras final Phase 3 ORIGIN 3 analysis for TRUTAKNA met all prespecified endpoints, including kidney-function preservation and reduced disease-progression events, supporting a supplemental FDA filing for full approval. Traders largely view the data as a major de-risking and commercial catalyst, though some argue it confirms an already accelerated-approved drug and are debating the muted, volatile reaction amid competitive concerns and possible sell-the-news pressure.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

Federal Reserve rate-hike expectations are driving the discussion around SOFI, with traders debating whether the move was already priced in and whether higher rates will support its banking spread or pressure lending demand and growth valuations. The community is sharply split, with bullish traders citing conservative guidance and long-term fintech growth while bearish traders focus on renewed rate pressure, dilution, and weak share performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned

FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with NDA resubmission planned in Q4 2026.read more...

Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript

Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-achieve-life-sciences-inc-stock...

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving Average   - Time to Sell?

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports...

ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?

Equity

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 


Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm...

What is Zacks Research's Estimate for ACHV FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on...

HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of Achieve Life Sciences in a research report issued...

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.

Achieve Life Sciences Inc.

Bearish Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Current Price	$7.91
Prev Close	$7.42
Open	$7.59
Dividend Yield	0.00%
50-Day Moving Average	$7.10
Beta	1.18
Avg. Volume	1.34M
PE Ratio	-5.11

52-Week High	$8.64
52-Week Low	$2.62
Market Capitalization	$763.54M
EPS (Annual)	-$1.25
Price to Book	-55.36
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACHV Fundamentals